Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/II Trial of SX-682 in Combination With Nivolumab for Refractory RAS Mutated (RAS) Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) (STOPTRAFFIC-1)

NCT04599140 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT04599140
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04599140 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/II Trial of SX-682 in Combination With Nivolumab for Refractory RAS Mutated (RAS) Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) (STOPTRAFFIC-1)
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 14, 2020
Completion date
July 31, 2026
Enrollment
51 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colon adenocarcinoma, metastatic colorectal carcinoma, metastatic rectal adenocarcinoma, stage iii colon cancer ajcc v8, stage iii rectal cancer ajcc v8, stage iiia colon cancer ajcc v8, stage iiia rectal cancer ajcc v8, stage iiib colon cancer ajcc v8, stage iiib rectal cancer ajcc v8, stage iiic colon cancer ajcc v8, stage iiic rectal cancer ajcc v8, stage iv colon cancer ajcc v8, stage iv rectal cancer ajcc v8, stage iva colon cancer ajcc v8, stage iva rectal cancer ajcc v8, stage ivb colon cancer ajcc v8, stage ivb rectal cancer ajcc v8, stage ivc colon cancer ajcc v8, stage ivc rectal cancer ajcc v8, unresectable colon adenocarcinoma, unresectable rectal adenocarcinoma